Can rosuvastatin cause weight gain

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Can Rosuvastatin Cause Weight Gain?

Introduction to Rosuvastatin and Weight Gain Concerns

Rosuvastatin, a widely used statin, is primarily prescribed to lower cholesterol levels and reduce the risk of cardiovascular diseases. However, there are concerns about whether rosuvastatin can cause weight gain, especially in patients with obesity or those on high-fat diets. This article synthesizes findings from multiple studies to address this concern.

Rosuvastatin and Body Weight in Animal Models

Effects on Weight Gain in Mice

Several studies have investigated the impact of rosuvastatin on body weight in animal models. In a study involving C57Bl/6 mice fed a high-fat diet, rosuvastatin treatment was found to decrease adiposity and adipocyte size, particularly at lower doses (10 mg/kg and 20 mg/kg) . This suggests that rosuvastatin may help reduce fat accumulation rather than contribute to weight gain.

Comparative Study in Female Rats

Another study compared the effects of simvastatin, rosuvastatin, and fenofibrate on body weight in female rats treated with oral contraceptives and a high-fat diet. The results indicated that while fenofibrate was the most effective in preventing weight gain, rosuvastatin did not significantly contribute to weight gain either . This further supports the notion that rosuvastatin does not inherently cause weight gain.

Metabolic Profile and Fat Distribution

Dose-Dependent Effects on Metabolic Health

Research has shown that rosuvastatin can have dose-dependent effects on the metabolic profile of diet-induced obese mice. Higher doses of rosuvastatin (40 mg/kg) were more effective in improving glucose tolerance and insulin sensitivity, which are critical factors in managing obesity and related metabolic disorders . This improvement in metabolic health could indirectly influence body weight management.

Redistribution of Fat Depots

Interestingly, rosuvastatin has been observed to change the pattern of fat distribution in mice. At higher doses, it promotes the storage of fat in subcutaneous rather than visceral depots, which is considered a healthier fat distribution pattern . This redistribution can improve overall metabolic health and potentially mitigate weight gain.

Rosuvastatin and Blood Pressure in Obese Mice

Blood Pressure and Insulin Sensitivity

In obese dyslipidemic mice, rosuvastatin was found to normalize blood pressure and its variability without affecting body weight significantly . This suggests that rosuvastatin's benefits on cardiovascular health and insulin sensitivity do not necessarily come with the side effect of weight gain.

Pharmacokinetics in Obese Rats

Impact of High-Fat Diet on Rosuvastatin Uptake

A study on the pharmacokinetics of rosuvastatin in rats with high-fat diet-induced obesity revealed that obesity could alter the drug's pharmacokinetics, leading to higher blood concentrations of rosuvastatin . However, this increase in blood concentration is more related to the risk of muscle toxicity rather than weight gain.

Conclusion

Based on the available research, rosuvastatin does not appear to cause weight gain. In fact, it may help reduce adiposity and improve metabolic health in a dose-dependent manner. While it can alter fat distribution and improve insulin sensitivity, these effects do not translate into significant weight gain. Therefore, patients concerned about weight gain while taking rosuvastatin can be reassured by these findings.

Sources and full results

Most relevant research papers on this topic

Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice

Rosuvastatin improves glucose intolerance, insulin sensitivity, and non-alcoholic fatty liver disease, and shifts fat distribution from visceral to subcutaneous depots in a mouse model of diet-induced obesity.

Very Rigorous Journal

2013·

27citations

·Rodrigo Neto-Ferreira et al.

THE EFFECTS OF SIMVASTATIN, ROSUVASTATIN, AND FENOFIBRATE ON THE BODY WEIGHT AND LIPID PROFILES OF FEMALE RATS TREATED WITH ORAL CONTRACEPTIVES AND A HIGH-FAT DIET

Fenofibrate effectively reduces weight gain and improves lipid profiles in female rats treated with oral contraceptives and a high-fat diet, while simvastatin and rosuvastatin show mixed results.

RCT

2022·

0citations

·Dwi Anggara Putri et al.

Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect

Rosuvastatin, at a dose of 40 mg/kg, can reduce glucometabolic changes and improve pancreatic -cell function in mice on a high-fat diet.

RCTAnimal Study

2019·

25citations

·H. Al-kuraishy et al.

Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.

Rosuvastatin effectively normalizes blood pressure and its variability in obese dyslipidaemic mice, with potential vasculoprotective effects due to increased PPARgamma and SOD1 expression in endothelium.

Non-RCTAnimal Study

2008·

50citations

·F. Desjardins et al.

The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity.

High-fat diet-induced obesity increases rosuvastatin blood concentration, suggesting a need to reduce dose for obese patients to avoid muscle toxicity risks.

Non-RCTAnimal Study

2020·

2citations

·Fan Zhang et al.

Tailoring of Rosuvastatin Calcium and Atenolol Bilayer Tablets for the Management of Hyperlipidemia Associated with Hypertension: A Preclinical Study

Bilayer rosuvastatin calcium and atenolol tablets effectively treat coexisting dyslipidemia and hypertension, reducing lipid profiles, slowing weight gain, and lowering blood pressure to normal levels in preclinical studies.

Non-RCTAnimal Study

2022·

20citations

·Mahmoud M. A. Elsayed et al.

Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE−/− mice exposed to a high cholesterol diet

Rosuvastatin reduces gliosis and accelerated weight gain in mice on a high cholesterol diet, potentially due to mechanisms independent of its lipid-lowering effect.

Non-RCTAnimal Study

2007·

10citations

·D. Famer et al.

Ascorbic acid co-administered with rosuvastatin reduces reproductive impairment in the male offspring from male rats exposed to the statin at pre-puberty.

Ascorbic acid supplementation co-administered with rosuvastatin reduces reproductive impairment in male offspring caused by statin treatment to fathers.

RCTAnimal Study

2018·

11citations

·Gabriel Adan Araújo Leite et al.

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study.

Rosuvastatin treatment significantly reduced LDL-C in children with familial hypercholesterolemia aged 6-17 years, with no adverse effects on growth or sexual maturation.

Non-RCT

2015·

45citations

·M. J. Braamskamp et al.

Lipid-lowering efficacy of rosuvastatin.

Rosuvastatin effectively reduces LDL-cholesterol by 46% to 55%, with a dose-dependent effect on total blood cholesterol, and increases HDL-cholesterol by 7%.

Meta-AnalysisVery Rigorous Journal

2017·

56citations

·S. Adams et al.

Try another search

how to curb addiction

therapy for anxiety

obsessive compulsive disorder treatment near me

depression in cats

exercise and depression

first line antihypertensive drugs